Robert R Henry Selected Research

volagidemab

1/2018

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert R Henry Research Topics

Disease

70	Type 2 Diabetes Mellitus (MODY) 01/2019 - 03/2002
44	Insulin Resistance 01/2020 - 03/2002
17	Weight Loss (Weight Reduction) 10/2018 - 08/2003
14	Obesity 01/2018 - 01/2003
13	Body Weight (Weight, Body) 06/2019 - 11/2006
12	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2019 - 01/2003
9	Hyperglycemia 06/2019 - 02/2004
9	Heart Failure 07/2016 - 09/2003
8	Inflammation (Inflammations) 01/2019 - 01/2003
8	Glucose Intolerance 12/2016 - 03/2007
7	Hypoglycemia (Reactive Hypoglycemia) 06/2019 - 02/2008
7	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 06/2019 - 03/2015
6	Weight Gain 01/2018 - 01/2002
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 01/2003
4	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 01/2020 - 05/2008
4	Dyslipidemias (Dyslipidemia) 01/2018 - 10/2002
4	Edema (Dropsy) 07/2014 - 09/2003
3	Acute Coronary Syndrome 01/2018 - 09/2013
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 06/2006
3	Nausea 01/2018 - 07/2012
3	Hypertension (High Blood Pressure) 02/2013 - 10/2002
3	Atherosclerosis 02/2013 - 01/2003
2	Injection Site Reaction 01/2018 - 07/2012
2	Coronary Disease (Coronary Heart Disease) 01/2018 - 09/2013
2	Ketosis 01/2017 - 04/2016
2	Vomiting 05/2014 - 07/2012
2	Hypertrophy 10/2013 - 03/2008
2	Abdominal Obesity 02/2012 - 10/2002
2	Disease Progression 07/2009 - 06/2009
2	Asthma (Bronchial Asthma) 06/2007 - 03/2003
1	Vascular Diseases (Vascular Disease) 10/2019
1	Myocardial Infarction 01/2018
1	Stroke (Strokes) 01/2018
1	Kidney Diseases (Kidney Disease) 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018

Drug/Important Bio-Agent (IBA)

41	Insulin (Novolin)FDA Link 01/2020 - 03/2002
40	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 03/2002
15	Pioglitazone (Actos)FDA Link 01/2020 - 01/2003
11	AdiponectinIBA 01/2018 - 03/2003
11	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 03/2002
10	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 06/2019 - 02/2008
10	Exenatide (Byetta)FDA Link 01/2018 - 11/2004
8	Sodium-Glucose Transport ProteinsIBA 06/2019 - 03/2014
8	LipidsIBA 01/2018 - 03/2002
7	Triglycerides (Triacylglycerol)IBA 01/2019 - 10/2002
7	IncretinsIBA 08/2013 - 11/2004
6	ThiazolidinedionesIBA 07/2012 - 01/2003
5	dapagliflozinIBA 11/2018 - 03/2014
5	Catechin (Z 7300)IBA 01/2018 - 02/2012
5	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2018 - 08/2003
5	Proteins (Proteins, Gene)FDA Link 11/2013 - 01/2005
5	Hormones (Hormone)IBA 08/2013 - 01/2003
4	Rosiglitazone (Avandia)FDA Link 01/2018 - 01/2003
4	alirocumabIBA 01/2018 - 01/2017
4	aleglitazarIBA 01/2018 - 07/2009
4	Sodium-Glucose Transporter 2 InhibitorsIBA 07/2016 - 07/2010
3	Blood Glucose (Blood Sugar)IBA 06/2019 - 01/2016
3	SodiumIBA 01/2019 - 09/2003
3	CanagliflozinIBA 01/2019 - 12/2015
3	Proprotein Convertase 9IBA 01/2018 - 01/2017
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 07/2009
3	Pharmaceutical PreparationsIBA 01/2018 - 09/2003
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 01/2017
3	HDL CholesterolIBA 01/2017 - 06/2006
3	oxidized low density lipoproteinIBA 01/2017 - 03/2002
3	Liraglutide FDA Link 05/2014 - 03/2010
3	C-Reactive ProteinIBA 02/2013 - 03/2002
3	Troglitazone (Rezulin)FDA Link 01/2003 - 01/2002
2	ClusterinIBA 01/2020 - 01/2020
2	MyokinesIBA 01/2019 - 01/2016
2	Adenosine Triphosphate (ATP)IBA 12/2018 - 10/2017
2	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 10/2018 - 12/2017
2	CholesterolIBA 01/2018 - 02/2009
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2018 - 05/2013
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2013
2	Nonesterified Fatty Acids (NEFA)IBA 01/2018 - 03/2008
2	LDL CholesterolIBA 12/2017 - 01/2017
2	KetonesIBA 04/2016 - 12/2015
2	Bile Acids and Salts (Bile Acids)IBA 09/2013 - 08/2008
2	LDL Lipoproteins (beta Lipoproteins)IBA 02/2013 - 10/2002
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 06/2012 - 05/2010
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 06/2012 - 03/2010
2	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2012 - 08/2008
2	Protein Isoforms (Isoforms)IBA 07/2010 - 09/2007
2	Hypoglycemic Agents (Hypoglycemics)IBA 08/2008 - 09/2003
1	Insulin ReceptorIBA 01/2020
1	Low Density Lipoprotein Receptor-Related Protein-2IBA 01/2020
1	perindopril drug combination indapamideIBA 10/2019
1	Gliclazide (Diamicron)IBA 10/2019
1	PalmitatesIBA 01/2019
1	SymportersIBA 01/2019
1	LipopolysaccharidesIBA 01/2019
1	Protons (Proton)IBA 01/2019
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018

Therapy/Procedure

28	Therapeutics 06/2019 - 03/2002
24	Glycemic Control 10/2019 - 03/2002
3	Injections 12/2017 - 01/2003
3	Drug Therapy (Chemotherapy) 10/2009 - 06/2009